MGC Competitors

Delisted . USA . 
Stock . MGC Pharmaceuticals
MGCLFDelisted Stock  USD 0.21  0.00  0.00%   
Analyzing MGC Pharmaceuticals competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of MGC Pharmaceuticals to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of MGC Pharmaceuticals competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.210.210.21
Details
Intrinsic
Valuation
LowRealHigh
0.190.190.23
Details
Naive
Forecast
LowNextHigh
0.210.210.21
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.180.240.30
Details

MGC Pharmaceuticals Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between MGC Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding otcs. A correlation of about +1.0 implies that the price of MGC and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of MGC Pharmaceuticals does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
AXRX
+ 1.0
LVTTF
AQSZF
+ 0.69
CBDNF
AQSZF
+ 0.48
CBDY
CBDY
+ 0.4
CBDNF
FLHLF
+ 0.29
AQSZF
SKYI
+ 0.24
CBDNF
  
High negative correlations   
BCBCF
- 0.59
AQSZF
BCBCF
- 0.53
CBDY
BCBCF
- 0.5
CBDNF
BCBCF
- 0.31
SFWJ
SFWJ
- 0.26
AQSZF
BCBCF
- 0.21
FLHLF

Risk-Adjusted Indicators

There is a big difference between MGC OTC Stock performing well and MGC Pharmaceuticals OTC Stock doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze MGC Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
CBDNF  3.63 (0.11) 0.00  0.16  0.00 
 0.00 
 14.75 
(13.33)
 47.67 
CBDY  8.88 (0.24) 0.00 (0.04) 0.00 
 0.00 
 14.29 
(22.22)
 76.03 
AQSZF  3.83 (0.76) 0.00  1.26  0.00 
 0.00 
 7.84 
(11.36)
 54.76 
FLHLF  11.48  0.82  0.06  0.36  12.54 
(18.35)
 31.04 
(21.33)
 91.17 
SKYI  21.35  6.14  0.11 (1.34) 19.00 
(69.77)
 56.25 
(52.94)
 250.98 
LVTTF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
SFWJ  15.25  4.07  0.16 (1.01) 14.01 
(26.48)
 48.08 
(27.27)
 185.19 
BCBCF  20.40  9.19  0.38  8.98  9.21 
(75.25)
 26.81 
(10.61)
 425.33 
AXRX  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
ANTCF  29.49  9.36  0.15  1.59  20.40 
(130.51)
 84.21 
(60.00)
 451.80 
All Fundamental Data

MGC Pharmaceuticals Competitive Analysis

The better you understand MGC Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, MGC Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across MGC Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
MGCLF CBDNF CBDY AQSZF FLHLF SKYI LVTTF SFWJ BCBCF AXRX
 0.00 
 0.21 
MGC
 0.00 
 0.06 
CBD
 26.32 
 0 
Target
 18.18 
 0.01 
Aequus
 3.15 
 0.04 
Filament
 56.25 
 0 
Sky
 0.00 
 0 
Levitee
 25.00 
 0.03 
Software
 1.66 
 0.07 
BCBCF
 0.00 
 0 
Amexdrug
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Out of control
Out of control
Out of control
Out of control
Very steady
Out of control
Out of control
Very steady
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Weak
Very Weak
Modest
Good
Very Weak
Good
Good
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Dangerous
Quite High
Low
Below Average
Average
Quite High
Low
Low
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Not Rated
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Current Ratio
0.84
0.09
0.17
0.78
4.1
N/A
N/A
N/A
6.38
1.35
Net Asset
22.6 M
2.09 M
13.06 M
4.35 M
17.84 M
N/A
12.97 M
N/A
1.95 M
2.31 M
Profit Margin
N/A
N/A
N/A
-1.36
N/A
N/A
N/A
N/A
-1.96
0.0181
EBITDA
(16.44 M)
(4.6 M)
2.23 M
(1.23 M)
(9.08 M)
N/A
(10.73 M)
N/A
(2.83 M)
380.83 K
Operating Margin
-3.28
-2.71
N/A
-1.31
-31.94
N/A
N/A
N/A
-1.82
0.0361
Current Valuation
24.97 M
14.44 M
4.2 M
3.03 M
7.57 M
22 M
2.27 M
N/A
1.82 M
34.51 M
Price To Book
5.69
N/A
7.83
32.78
0.85
N/A
0.0903
N/A
3.14
51.38
Retained Earnings
N/A
N/A
N/A
(5.72 M)
N/A
N/A
N/A
N/A
N/A
961 K
Current Asset
N/A
N/A
N/A
458 K
N/A
N/A
N/A
N/A
N/A
1.76 M
Beta
1.23
0.49
-0.51
0.44
N/A
2.37
N/A
234.21
N/A
-0.72
Number Of Employees
16
2
61
14
11
1
9
2
4
9
Shares Outstanding
2.87 B
49.46 M
617.03 M
132.63 M
174.95 M
110.02 M
100.42 M
N/A
53.02 M
169.11 M
Cash Flow From Operations
(12.16 M)
(1.14 M)
100.12 K
(1.17 M)
(5.41 M)
(12.55 K)
(4.63 M)
N/A
(875.7 K)
27.49 K
Annual Yield
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Debt
4.35 M
1.34 M
1.72 M
26.09 K
868.91 K
33.67 K
N/A
N/A
94.47 K
961.12 K
Return On Equity
-2.19
N/A
-23.05
-2.92
-0.4
N/A
N/A
N/A
-0.32
0.29
Z Score
1.8
-4.2
0.6
93.4
5.4
N/A
N/A
N/A
21.9
14.2
Return On Asset
-0.45
-1.38
-0.0596
-0.42
-0.21
N/A
N/A
N/A
-0.18
0.11
Book Value Per Share
0.002
-0.26
-0.005
-0.003
0.084
N/A
N/A
N/A
0.022
0.004
Current Liabilities
N/A
N/A
N/A
704 K
N/A
N/A
N/A
N/A
N/A
798 K
Total Asset
22.6 M
2.09 M
13.06 M
4.35 M
17.84 M
N/A
12.97 M
N/A
1.95 M
2.31 M
Debt To Equity
0.84
N/A
1.82
1.39
0.059
N/A
N/A
N/A
0.066
1.46
Target Price
N/A
N/A
N/A
N/A
1.5
N/A
N/A
N/A
N/A
N/A
Last Dividend Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Shares Owned By Institutions
6.12
N/A
N/A
N/A
0.18
N/A
N/A
N/A
N/A
N/A
Market Capitalization
17.2 M
5.93 M
2.47 M
4.12 M
8.08 M
22 M
401.67 K
N/A
4.03 M
16.91 M
Price To Earning
N/A
N/A
N/A
-1.79
N/A
N/A
N/A
N/A
N/A
165.0
Price To Sales
5.81
2.79
340.13
1.44
103.44
N/A
0.053
N/A
4.63
3.04
Net Income
(20.35 M)
(5.25 M)
272.88 K
(1.81 M)
(9.25 M)
(13.77 K)
(11.4 M)
N/A
(2.86 M)
111.36 K
Earnings Per Share
-0.005
-0.11
N/A
-0.01
-0.042
N/A
N/A
N/A
N/A
N/A
Shares Owned By Insiders
9.1
26.61
11.37
14.96
66.23
N/A
37.49
N/A
66.39
N/A
Revenue
4.65 M
166.95 K
N/A
2.71 M
N/A
N/A
1.72 M
N/A
151
10.43 M
Working Capital
N/A
N/A
N/A
(246 K)
N/A
N/A
N/A
N/A
N/A
966 K
Cash And Equivalents
1.89 M
59.92 K
114.21 K
1.39 M
3 M
N/A
N/A
N/A
740.29 K
168.01 K
Cash Per Share
N/A
N/A
N/A
0.01
0.02
N/A
N/A
N/A
0.02
N/A
Gross Profit
562.87 K
3.61 K
5 K
2.69 M
N/A
N/A
N/A
N/A
(983)
1.01 M
Day Typical Price
0.21
0.06
0.0014
0.0065
0.0361
0.0025
0.0027
0.025
0.0646
0.002
Accumulation Distribution
N/A
N/A
N/A
N/A
678.5
N/A
N/A
N/A
0.1
N/A
Market Facilitation Index
N/A
N/A
N/A
N/A
0.0
N/A
N/A
N/A
0.007
N/A
Daily Balance Of Power
0.0
0.0
(9,223,372,036,855)
9.2 T
(0.11)
9.2 T
0.0
9.2 T
(0.16)
0.0
Period Momentum Indicator
N/A
N/A
(0.0005)
0.001
(0)
9.0E-4
N/A
0.005
(0)
N/A
Rate Of Daily Change
1.0
1.0
0.74
1.18
0.97
1.56
1.0
1.25
0.98
1.0
Day Median Price
0.21
0.06
0.0014
0.0065
0.0341
0.0025
0.0027
0.025
0.0644
0.002
Price Action Indicator
N/A
N/A
(0.0003)
5.0E-4
0.0053
5.0E-4
N/A
0.0025
1.0E-4
N/A
Coefficient Of Variation
(865.51)
(2,499)
(27,380)
(1,062)
1428.6
718.06
N/A
708.86
624.05
N/A
Mean Deviation
1.17
3.63
8.88
3.83
11.48
21.35
N/A
15.25
20.4
N/A
Jensen Alpha
(0.41)
(0.11)
(0.24)
(0.76)
0.8237
6.14
N/A
4.07
9.19
N/A
Total Risk Alpha
(0.84)
(1.27)
(2.13)
(2.03)
(1.17)
(0.05)
N/A
0.0148
1.16
N/A
Sortino Ratio
N/A
N/A
N/A
N/A
0.0602
0.1126
N/A
0.1564
0.376
N/A
Downside Variance
N/A
N/A
N/A
N/A
303.29
2474.89
N/A
529.08
598.31
N/A
Standard Deviation
3.26
7.02
14.74
8.62
16.57
41.02
N/A
26.29
58.09
N/A
Kurtosis
32.44
4.24
5.29
12.59
0.8169
8.93
N/A
9.51
35.58
N/A
Potential Upside
N/A
14.75
14.29
7.84
31.04
56.25
N/A
48.08
26.81
N/A
Treynor Ratio
(1.64)
0.1632
(0.04)
1.26
0.3588
(1.34)
N/A
(1.01)
8.98
N/A
Maximum Drawdown
29.91
47.67
76.03
54.76
91.17
250.98
N/A
185.19
425.33
N/A
Variance
10.6
49.28
217.2
74.33
274.61
1682.63
N/A
691.32
3374.33
N/A
Market Risk Adjusted Performance
(1.63)
0.1732
(0.03)
1.27
0.3688
(1.33)
N/A
(1.00)
8.99
N/A
Risk Adjusted Performance
(0.08)
(0.02)
0.0069
(0.06)
0.0604
0.111
N/A
0.1122
0.1263
N/A
Skewness
(4.78)
0.1487
1.4
(2.43)
0.3769
2.48
N/A
2.32
5.77
N/A
Semi Deviation
N/A
N/A
N/A
N/A
12.54
19.0
N/A
14.01
9.21
N/A
Information Ratio
(0.15)
(0.06)
(0.01)
(0.11)
0.0633
0.1365
N/A
0.1368
0.1583
N/A
Value At Risk
(3.70)
(13.33)
(22.22)
(11.36)
(21.33)
(52.94)
N/A
(27.27)
(10.61)
N/A
Expected Short fall
N/A
N/A
N/A
N/A
(18.35)
(69.77)
N/A
(26.48)
(75.25)
N/A
Downside Deviation
N/A
N/A
N/A
N/A
17.42
49.75
N/A
23.0
24.46
N/A
Semi Variance
N/A
N/A
N/A
N/A
157.36
360.83
N/A
196.38
84.8
N/A

MGC Pharmaceuticals Competition Performance Charts

Five steps to successful analysis of MGC Pharmaceuticals Competition

MGC Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by MGC Pharmaceuticals in relation to its competition. MGC Pharmaceuticals' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of MGC Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact MGC Pharmaceuticals' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to MGC Pharmaceuticals, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your MGC Pharmaceuticals position

In addition to having MGC Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Latest Losers Thematic Idea Now

Latest Losers
Latest Losers Theme
Dynamically computed list of top equities currently sorted across major exchanges. The Latest Losers theme has 215 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Latest Losers Theme or any other thematic opportunities.
View All  Next Launch
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Other Consideration for investing in MGC OTC Stock

If you are still planning to invest in MGC Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MGC Pharmaceuticals' history and understand the potential risks before investing.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY